184 related articles for article (PubMed ID: 32595215)
1. Emerging roles for the GPI-anchored tumor suppressor OPCML in cancers.
Antony J; Zanini E; Birtley JR; Gabra H; Recchi C
Cancer Gene Ther; 2021 Feb; 28(1-2):18-26. PubMed ID: 32595215
[TBL] [Abstract][Full Text] [Related]
2. The Tumor-Suppressor Protein OPCML Potentiates Anti-EGFR- and Anti-HER2-Targeted Therapy in HER2-Positive Ovarian and Breast Cancer.
Zanini E; Louis LS; Antony J; Karali E; Okon IS; McKie AB; Vaughan S; El-Bahrawy M; Stebbing J; Recchi C; Gabra H
Mol Cancer Ther; 2017 Oct; 16(10):2246-2256. PubMed ID: 28775148
[TBL] [Abstract][Full Text] [Related]
3. The tumour suppressor OPCML promotes AXL inactivation by the phosphatase PTPRG in ovarian cancer.
Antony J; Zanini E; Kelly Z; Tan TZ; Karali E; Alomary M; Jung Y; Nixon K; Cunnea P; Fotopoulou C; Paterson A; Roy-Nawathe S; Mills GB; Huang RY; Thiery JP; Gabra H; Recchi C
EMBO Rep; 2018 Aug; 19(8):. PubMed ID: 29907679
[TBL] [Abstract][Full Text] [Related]
4. The OPCML tumor suppressor functions as a cell surface repressor-adaptor, negatively regulating receptor tyrosine kinases in epithelial ovarian cancer.
McKie AB; Vaughan S; Zanini E; Okon IS; Louis L; de Sousa C; Greene MI; Wang Q; Agarwal R; Shaposhnikov D; Wong JL; Gungor H; Janczar S; El-Bahrawy M; Lam EW; Chayen NE; Gabra H
Cancer Discov; 2012 Feb; 2(2):156-71. PubMed ID: 22585860
[TBL] [Abstract][Full Text] [Related]
5. Inactivating mutations and X-ray crystal structure of the tumor suppressor OPCML reveal cancer-associated functions.
Birtley JR; Alomary M; Zanini E; Antony J; Maben Z; Weaver GC; Von Arx C; Mura M; Marinho AT; Lu H; Morecroft EVN; Karali E; Chayen NE; Tate EW; Jurewicz M; Stern LJ; Recchi C; Gabra H
Nat Commun; 2019 Jul; 10(1):3134. PubMed ID: 31316070
[TBL] [Abstract][Full Text] [Related]
6. OPCML is a broad tumor suppressor for multiple carcinomas and lymphomas with frequently epigenetic inactivation.
Cui Y; Ying Y; van Hasselt A; Ng KM; Yu J; Zhang Q; Jin J; Liu D; Rhim JS; Rha SY; Loyo M; Chan AT; Srivastava G; Tsao GS; Sellar GC; Sung JJ; Sidransky D; Tao Q
PLoS One; 2008 Aug; 3(8):e2990. PubMed ID: 18714356
[TBL] [Abstract][Full Text] [Related]
7. Combined OPCML and AXL Expression as a Prognostic Marker and OPCML Enhances AXL Inhibitor in Cholangiocarcinoma.
Khamko R; Wasenang W; Daduang J; Settasatian C; Limpaiboon T
In Vivo; 2022; 36(3):1168-1177. PubMed ID: 35478117
[TBL] [Abstract][Full Text] [Related]
8. Expression and promoter methylation status of OPCML and its functions in the inhibition of cell proliferation, migration, and invasion in breast cancer.
Lian B; Li H; Liu Y; Chai D; Gao Y; Zhang Y; Zhou J; Li J
Breast Cancer; 2021 Mar; 28(2):448-458. PubMed ID: 33108608
[TBL] [Abstract][Full Text] [Related]
9.
Khamko R; Daduang J; Settasatian C; Limpaiboon T
Cancer Genomics Proteomics; 2021; 18(6):771-780. PubMed ID: 34697068
[TBL] [Abstract][Full Text] [Related]
10. Down-regulated expression of OPCML predicts an unfavorable prognosis and promotes disease progression in human gastric cancer.
Xing X; Cai W; Ma S; Wang Y; Shi H; Li M; Jiao J; Yang Y; Liu L; Zhang X; Chen M
BMC Cancer; 2017 Apr; 17(1):268. PubMed ID: 28407749
[TBL] [Abstract][Full Text] [Related]
11. RAS-mediated epigenetic inactivation of OPCML in oncogenic transformation of human ovarian surface epithelial cells.
Mei FC; Young TW; Liu J; Cheng X
FASEB J; 2006 Mar; 20(3):497-9. PubMed ID: 16384911
[TBL] [Abstract][Full Text] [Related]
12. OPCML at 11q25 is epigenetically inactivated and has tumor-suppressor function in epithelial ovarian cancer.
Sellar GC; Watt KP; Rabiasz GJ; Stronach EA; Li L; Miller EP; Massie CE; Miller J; Contreras-Moreira B; Scott D; Brown I; Williams AR; Bates PA; Smyth JF; Gabra H
Nat Genet; 2003 Jul; 34(3):337-43. PubMed ID: 12819783
[TBL] [Abstract][Full Text] [Related]
13. Methylation of OPCML promoter in ovarian cancer tissues predicts poor patient survival.
Zhou F; Tao G; Chen X; Xie W; Liu M; Cao X
Clin Chem Lab Med; 2014 May; 52(5):735-42. PubMed ID: 24327526
[TBL] [Abstract][Full Text] [Related]
14. Expression of cellular adhesion molecule 'OPCML' is down-regulated in gliomas and other brain tumours.
Reed JE; Dunn JR; du Plessis DG; Shaw EJ; Reeves P; Gee AL; Warnke PC; Sellar GC; Moss DJ; Walker C
Neuropathol Appl Neurobiol; 2007 Feb; 33(1):77-85. PubMed ID: 17239010
[TBL] [Abstract][Full Text] [Related]
15. OPCML: A Promising Biomarker and Therapeutic Avenue.
Simovic I; Castaño-Rodríguez N; Kaakoush NO
Trends Cancer; 2019 Aug; 5(8):463-466. PubMed ID: 31421903
[TBL] [Abstract][Full Text] [Related]
16. The Risk Genes for Neuropsychiatric Disorders
Habicher J; Sanvido I; Bühler A; Sartori S; Piccoli G; Carl M
Genes (Basel); 2024 Mar; 15(3):. PubMed ID: 38540422
[TBL] [Abstract][Full Text] [Related]
17. Expression of ovarian tumour suppressor OPCML in the female CD-1 mouse reproductive tract.
Fleming JS; McQuillan HJ; Millier MJ; Sellar GC
Reproduction; 2009 Apr; 137(4):721-6. PubMed ID: 19176311
[TBL] [Abstract][Full Text] [Related]
18. New roles opined for OPCML.
Wu SY; Sood AK
Cancer Discov; 2012 Feb; 2(2):115-6. PubMed ID: 22585855
[TBL] [Abstract][Full Text] [Related]
19. Prognostic value of opioid binding protein/cell adhesion molecule-like promoter methylation in bladder carcinoma.
Duarte-Pereira S; Paiva F; Costa VL; Ramalho-Carvalho J; Savva-Bordalo J; Rodrigues A; Ribeiro FR; Silva VM; Oliveira J; Henrique R; Jerónimo C
Eur J Cancer; 2011 May; 47(7):1106-14. PubMed ID: 21273058
[TBL] [Abstract][Full Text] [Related]
20. Loss of OPCML expression and the correlation with CpG island methylation and LOH in ovarian serous carcinoma.
Chen H; Ye F; Zhang J; Lu W; Cheng Q; Xie X
Eur J Gynaecol Oncol; 2007; 28(6):464-7. PubMed ID: 18179137
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
